Intech Investment Management LLC Buys Shares of 11,323 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Intech Investment Management LLC purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,323 shares of the specialty pharmaceutical company’s stock, valued at approximately $303,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Commonwealth Equity Services LLC raised its holdings in Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after buying an additional 350 shares during the last quarter. Covestor Ltd boosted its position in shares of Supernus Pharmaceuticals by 15.3% during the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock valued at $92,000 after buying an additional 358 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after buying an additional 600 shares in the last quarter. Texas Permanent School Fund Corp raised its position in Supernus Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company’s stock worth $1,631,000 after buying an additional 619 shares during the last quarter. Finally, Fidelis Capital Partners LLC bought a new position in Supernus Pharmaceuticals during the 1st quarter valued at about $33,000.

Supernus Pharmaceuticals Trading Down 0.1 %

SUPN opened at $30.75 on Friday. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -106.03 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $35.44. The company’s 50 day moving average is $32.27 and its 200 day moving average is $30.43.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.39 by ($0.03). The firm had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.02) EPS. As a group, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of research analyst reports. Piper Sandler lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $41.00 to $36.00 in a research note on Wednesday, September 11th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.